Using nanoparticles, Yale researchers have developed a drug-delivery system that could reduce organ transplant complications by hiding the donated tissue from the recipient’s immune system.
About 25,000 organ transplants are performed in the U.S. each year. Despite significant advances in the field, short-term and long-term organ rejection still poses a risk (rejection rates vary depending on the type of organ). The risk of rejection is even higher when the donor is deceased, due to organ damage.
T cells, the white blood cells that identify and attack foreign bodies, are one of the main culprits behind organ rejection. The most potent of these, known as effector memory T cells, are activated by a group of proteins known as human leukocyte antigens (HLAs) on the surface of endothelial cells lining the donated organ’s blood vessels. Researchers can silence the proteins with small interfering RNA (siRNA), a double-stranded RNA that hinders the expression of targeted genes. When delivered conventionally, however, the effects of siRNA last only a few days. A transplanted organ from a deceased donor typically needs weeks to “heal” and reduce the risk of rejection. The siRNA can also cause side effects in endothelial cells of other organs, which don’t need treatment, when administered to the whole body.
To give the siRNA more staying power, the researchers developed a drug delivery system in which polymer-based nanoparticles carry siRNA to the site of the graft and slowly release the drug. They also developed methods for introducing the nanoparticles into the donor organ before it is transplanted, so that only the organ is treated, not the whole body. The results of their work are published in the journal Nature Communications.
The particles — made in the Yale lab of Mark Saltzman, the Goizueta Foundation Professor of Chemical and Biomedical Engineering — can be tuned for specific properties. Saltzman, who is also a member of the Yale Cancer Center, said these nanoparticles were designed to have a slight positive charge to interact with the negative charge of the siRNA’s nucleic acid. This affinity between the two materials makes the particle a natural carrier for the drug, unlike commercially available nanoparticles that can hold only a limited amount of the drug.
For the study, the researchers treated part of a human artery — a few millimeters in diameter — with the siRNA-loaded nanoparticles and transplanted it into the abdominal aorta of an immune-deficient mouse inoculated with human T cells. The researchers found that the nanoparticles were still present in the donated tissue and significantly silenced the proteins’ expression up to six weeks after transplantation. Additionally, there was no damage to the endothelial cells of untargeted organs.
The first few weeks after the transplant are critical, especially when the organ donor is deceased, said Jordan Pober, the Bayer Professor of Translational Medicine and professor of immunobiology, pathology, and dermatology at Yale.
“If we delay the start of the rejection response, it should be milder and more easily controlled and lead to less late rejection,” said Pober, who is a co-author of the study and also director of Yale’s Human and Translational Immunology program.
Focusing on kidney transplants (by far the most common type of organ transplant performed), Saltzman and Pober are looking to apply the delivery system to a process known as ex vivo normothermic machine perfusion. Developed for kidneys by colleagues at Cambridge University, the process involves pumping warm, oxygenated red blood cells through an organ removed from a deceased donor to repair any damage to the organ before implanting it in the recipient. The Yale researchers plan to add the nanoparticles to the red blood cells to provide controlled delivery of the siRNA to the kidney’s endothelial cells.
The Latest on: Nanoparticle-based drug-delivery system
- 12 Student Startup Teams Compete For $96,000 Cash Prize Pool in U of A's Heartland Challengeon April 14, 2021 at 10:05 pm
The Heartland Challenge, a global student startup competition designed to simulate the process of raising venture capital with a cash prize pool of $96,000, kicks off at 5 p.m. today, Thursday, April ...
- Tattoo made of gold nanoparticles revolutionizes medical diagnosticson April 5, 2021 at 5:00 pm
There is also the problem of implant rejection as the immune system recognizes the sensor ... In the future, gold nanoparticle-based implantable sensors could be used to observe concentrations ...
- Nanoparticle-based thymulin gene therapy therapeutically reverses key pathology of experimental allergic asthmaon April 5, 2021 at 5:00 pm
(A) Experimental animal groups and timeline for “therapeutic” nanoparticle-based thymulin gene therapy study. Mice are intraperitoneally (i.p.) sensitized and intratracheally (i.t.) challenged.
- Lipid/PAA-coated mesoporous silica nanoparticles for dual-pH-responsive codelivery of arsenic trioxide/paclitaxel against breast cancer cellson April 5, 2021 at 5:00 pm
Nanomedicine has attracted increasing attention and emerged as a safer and more effective modality in cancer treatment than conventional chemotherapy. In particular, the distinction of tumor ...
- Enhanced drug delivery to the reproductive tract using nanomedicine reveals therapeutic options for prevention of preterm birthon April 4, 2021 at 5:01 pm
Mucus is the primary barrier to drug absorption and retention, and the physiology and structure of the various epithelial surfaces further limit effective drug delivery (12, 13). We have previously ...
- Cancer Nanomedicine: From Drug Delivery to Imagingon April 4, 2021 at 5:01 pm
In particular, extensive work with liposomal and polymer drug delivery vehicles has revealed that complexes ... cleared by the liver and phagocytic cells of the reticuloendothelial system (43). Rapid ...
- Nanoparticles that do not adhere to mucus provide uniform and long-lasting drug delivery to airways following inhalationon April 4, 2021 at 5:01 pm
See allHide authors and affiliations Mucoadhesive particles (MAP) have been widely explored for pulmonary drug delivery because of their perceived benefits in improving particle residence in the lungs ...
- A Nanoparticle-Based Universal Flu Vaccine Moves Closer to Useon April 4, 2021 at 1:44 am
There are many different influenza viruses, which cause an estimated 290,000 to 650,000 deaths every year. That range depends on many factors, including the illness that the virus causes, and how well ...
- Nanomedicinal Strategies to Treat Multidrug-resistant Tumors: Current Progresson March 23, 2021 at 5:00 pm
This has, in turn, led to the development of several nanoparticle-based drug delivery systems that have incorporated these excipients to overcome MDR. Despite the fact that the mechanisms to ...
- Nanoparticle-based vaccine offers new approach to COVID-19 immunityon March 19, 2021 at 3:01 am
This new candidate provides an alternative approach – using inert nanoparticles to carry the RBD and display it to the immune system. Delivering the RBD ... an attractive biomaterial for vaccine and ...
via Google News and Bing News